Bioprocessing Market is expected to reach US$ 72.55 billion by 2031

Instruments Segment to Hold Significant Bioprocessing Market Share During 2023–2031  

According to our latest study on "Bioprocessing Market Forecast to 2031 – Global Analysis – Product, Scale of Operation, Process, Application, End User, and Geography," the market is expected to reach US$ 72.55 billion by 2031 from US$ 25.35 billion in 2023. the market is estimated to register a CAGR of 14.0% during 2023–2031.

The report emphasizes the key factors driving the market and prominent players' developments. Factors such as the increasing prevalence of chronic diseases and the growing biopharmaceutical industry propel the bioprocessing market growth. However, the stringent regulatory policies and limitations associated with bioprocessing impede the market growth.  

Bioprocessing increases the number of living cells or other biological systems/components (such as bacteria, enzymes, proteins, viruses, or nucleic acids) in a commercial bioreactor for biopharmaceutical manufacturing. Products produced in the bioprocessing sector typically contain high-quality therapeutics and vaccines critical to modern healthcare advancement. The current bioprocessing industry landscape is characterized by dynamic developments driven by advances in biotechnology and increasing demand for biopharmaceuticals. The increase in demand is attributed to the prevalence of chronic diseases, the growing adoption of personalized medicine, and increasing bioprocessing applications in various sectors. As bioprocessing becomes significantly important in producing therapeutic proteins, vaccines, and other bio-based products, it turns out to be a key enabler of the biotechnological revolution. The market is progressing toward meeting the demands of a changing healthcare landscape, and the need for efficient and scalable bioproduction processes is expected to bring new bioprocessing market trends in the coming years.

Bioprocessing Market, by Region, 2023 (%)

Source: The Insight Partners Analysis

Proliferating Demand for Personalized Medicine to Provide Market Opportunities in Coming Years

The transformation of the healthcare industry from one-size-fits-all to a targeted approach is expanding the demand for personalized medicine. Precision medicine is being considered as one of the most promising approaches to tackle health concerns such as cancer, neurodegenerative diseases, and rare genetic conditions. Innovations in the production of personalized medicines are likely to impact the entire sector, and single-use technologies aimed at smaller-volume production have potential applications in protein bioproduction, particularly in downstream processes. Personalized and differentiated approaches to medicine are leading to a need for a wider range of products—many of them for a relatively small group of patients. Therefore, a fundamentally different approach to the production and delivery of biological products may be required.

Precision medicine utilizes the genomic information of an individual to offer targeted treatment for a particular indication. The growing number of orphan diseases has increased the demand for biologics and drugs, which has subsequently boosted the growth of personalized medicines. In 2019, the FDA approved ~12 personalized medications for addressing the root causes of disease and further integrated precision medicine with clinical care. Also, increasing government efforts are strengthening personalized medicine research activities. For instance, in February 2020, the National Human Genome Research Institute (NHGRI) announced to establish a new precision medicine and genomics program. This program focuses on the innovation of genomics and informatics tools for better diagnosis and treatment of disease.

Personalized medicines leverage advances in genetics and bioinformatics to target specific patient populations and treat previously untreatable diseases. Personalized medicine uses bioprocessing techniques to develop tailored therapies. From isolating specific cells to developing patient-specific treatments, bioprocessing steps are essential for producing treatments tailored to each patient. Therefore, the rising demand for personalized medicine is predicted to offer significant opportunities for bioprocessing market growth to the players operating in the market during the forecast period.

Bioprocessing Market, by Product:

Based on the product, the bioprocessing market analysis is carried out by considering the following segments: instruments, consumables, and accessories. The instruments segment held a larger market share in 2023 and is anticipated to register a higher CAGR of 14.5% during the forecast period. The instrument segment includes chromatography systems, filtration devices, osmometers, incubators, centrifuges, drying devices, and bioreactors. From pilot to process scale, chromatography systems are intended to provide persistent performance with processing flexibility as per the client's requirement. Sartorius AG offers Resolute BioSC Pilot Multi-Column Chromatography Systems—configurable automated systems with scalability that boost comprehensive support in pre-and post-sales. Ongoing advancements in bioreactor designs have led to the development of sophisticated systems capable of accommodating a range of cell types, from mammalian and microbial cells to plant and insect cells. Moreover, the use of single-use and flexible bioreactor technologies has gained prominence, offering scalability, flexibility, and reduced contamination risks. Advances in filtration technologies have led to the development of advanced filter media, such as depth filters, membrane filters, and chromatographic resins, offering enhanced capture efficiency, scalability, and purity for bioprocessing applications.

Bioprocessing Market, by Scale of Operation:

In terms of scale of operation, the bioprocessing market is bifurcated into commercial operations and clinical operations. The commercial operations segment held a larger market share in 2023 and is anticipated to register a higher CAGR during the forecast period.

Bioprocessing Market, by Process:

By process, the market is segmented into downstream bioprocess and upstream bioprocess. The downstream bioprocess segment dominated the bioprocessing market share in 2023 and is anticipated to register a higher CAGR of 14.4% during the forecast period. The upstream bioprocess accounted for 31.2% of the market share. Upstream bioprocessing is critical for the product's success, as it sets the foundation for the quality and quantity of the resultant product. Upstream bioprocessing points toward the initial stages of the production process in which microbes, cells, and bacteria are grown, nurtured, and developed through various technologies and media. These steps are complex and challenging, as high control is required over cell cultures and the environment in which cells are grown. The stages of upstream bioprocessing are cell isolation, cultivation, cell banking, and culture expansion. Furthermore, it is anticipated that technologies such as artificial intelligence and machine learning will be essential in upstream bioprocessing.

Bioprocessing Market, by Geography:

The geographic scope of the bioprocessing market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). The market in North America held the largest share in 2023. It was valued at 12.44 billion in 2023 and is expected to register a CAGR of 14.2% during 2023–2031. The growth of the market in North America was attributed to the increasing incidence of rare diseases and the rising trend of cell and gene therapy (CGT). The strategic presence of key players positioned in North America drives the expansion of the bioprocessing market size. The US held the largest market share in 2023 in North America. The growth of the biopharmaceutical sector, mainly due to technological advancements, increasing flexibility, and low operational costs, also benefits the bioprocessing market in the US. As per the International Trade Administration (ITA), the US is the largest market for biopharmaceuticals and the global leader in R&D. According to the PhRMA, companies in the US account for nearly 50% of the global biopharmaceutical R&D work, and they have succeeded in developing many novel medicines for which they hold intellectual property rights.

Apart from factors driving the market, the bioprocessing market report emphasizes major developments by prominent players. Cytiva (Danaher Corporation), Sartorius AG, Thermo Fisher Scientific Inc., Repligen Corporation, Merck KgaA, 3M Company, Getinge AB, Eppendorf SE, Corning Incorporated, Entegris, Agilent Technologies, and Bio-Rad Laboratories are among the prominent players operating in the market.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com